Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00438984 · ClinicalTrials.gov registry record · Phase 1
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00438984 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium. The registered enrollment target is 11 participants.
The verdict
NCT00438984, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as therapeutic autologous lymphocytes, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclophosphamide may also stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate white blood cells to kill tumor cells. Giving therapeutic autologous lymphocytes together with cyclophosphamide and aldesleukin may be an effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects of giving therapeutic autologous lymphocytes together with cyclophosphamide and aldesleukin in treating patients with stage IV melanoma
Interventions
- DRUG cyclophosphamide
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00438984
The ClinicalTrials.gov registry entry for NCT00438984 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00438984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00438984 about?
NCT00438984 is a clinical study titled "Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma". RATIONALE: Biological therapies, such as therapeutic autologous lymphocytes, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cell...
What is the current status of trial NCT00438984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2006-12. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00438984?
The interventions under investigation include: cyclophosphamide (DRUG), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00438984?
This trial is sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.